Por Renan Filho · 2026-11-05
**Lead**
The United States, long a pillar of global health security, is facing mounting criticism from economists and public health experts who warn that a combination of budgetary retrenchment and strategic disengagement could inadvertently spark a new influenza pandemic. The prospect, though not inevitable, has triggered alarm in financial circles, where the memory of COVID‑19’s multi‑trillion‑dollar economic scarring remains vivid. With the US Centers for Disease Control and Prevention (CDC) operating under a reduced real‑terms budget and the country having formally withdrawn from the World Health Organization (WHO) in 2026, the architecture that once helped contain emerging flu strains is showing cracks. The question now is whether these cracks will widen into a full‑blown global health emergency, and what that would mean for Britain’s economy.
**Contexto**
The origins of the present concern lie in a series of policy decisions taken in Washington over the past two years. The current administration’s “America First” health agenda has slashed funding for international disease surveillance programmes, including those that track avian influenza mutations in Southeast Asia and the Americas. At the same time, the CDC’s domestic influenza laboratory network, which performs critical genetic sequencing and vaccine strain selection, has seen its discretionary budget cut by approximately 15 per cent in real terms, according to congressional appropriations documents. These cuts have slowed the timely sharing of viral sequence data with international partners, including the UK’s Health Security Agency (UKHSA).
Economists point to the COVID‑19 pandemic as a stark precedent. The World Bank has estimated that the global economy contracted by roughly 3.5 per cent in 2020, with the UK suffering a 9.3 per cent fall in GDP. Even a moderately severe flu pandemic today, with lower mortality than COVID but higher transmissibility, could trigger supply‑chain disruptions, labour shortages, and a surge in public debt. The UK, heavily reliant on trade with the United States and with a healthcare system already under strain, would be particularly vulnerable. Any breakdown in US surveillance would delay the identification of a novel flu strain, giving it more time to circulate silently before travel restrictions and vaccine development can begin.
**Analise**
The economic logic behind the US disengagement is often presented as a cost‑saving measure, but the calculus may be dangerously short‑sighted. Pandemic preparedness is a classic public good: its benefits are global and diffuse, while its costs are immediate and concentrated. By reducing its contributions to the WHO and scaling back its own surveillance networks, the United States is effectively free‑riding on the efforts of other nations, including the UK. This creates a collective action problem. If every major economy followed the same logic, the world would be left without the early‑warning systems needed to prevent a localised outbreak from becoming a pandemic. The UK’s own investment in the UKHSA’s flu genomics programme, while robust, cannot substitute for gaps in US data collection.
Moreover, the economic impact of a pandemic is not limited to healthcare costs. The 1918 Spanish flu, for example, is estimated by economic historians to have reduced US manufacturing output by 20 per cent and caused a sharp contraction in global trade. Modern economies are even more interconnected. The US remains Britain’s largest single export market, worth over £60 billion annually. A pandemic that disrupts US consumer demand or closes ports would hit British exports in sectors from aerospace to whisky. The pharmaceutical supply chain, heavily reliant on US‑based active ingredient manufacturers, would also face severe bottlenecks. Vaccine nationalism, already a feature of the COVID‑19 pandemic, could recur, leaving the UK scrambling for doses if the US prioritises domestic production.
**Fontes**
This article draws on publicly available information from the following sources: the US Centers for Disease Control and Prevention budget documents for fiscal year 2026; the World Health Organization’s Global Influenza Surveillance and Response System reports; the UK Health Security Agency’s annual influenza threat assessment; the World Bank’s economic impact studies on COVID‑19; and historical economic analyses of the 1918 influenza pandemic published by the National Bureau of Economic Research. No direct quotes from named individuals have been used, and all figures cited are from official or peer‑reviewed sources.